MICROLUT levonorgestrel 30 mcg tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

microlut levonorgestrel 30 mcg tablet blister pack

bayer australia ltd - levonorgestrel, quantity: 30 microgram - tablet, sugar coated - excipient ingredients: lactose monohydrate; maize starch; povidone; purified talc; magnesium stearate; sucrose; macrogol 6000; calcium carbonate; glycol montanate - oral contraception

MICROGYNON 20 ED tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

microgynon 20 ed tablet blister pack

bayer australia ltd - levonorgestrel, quantity: 100 microgram; ethinylestradiol, quantity: 20 microgram - tablet, sugar coated - excipient ingredients: macrogol 6000; maize starch; purified talc; lactose monohydrate; povidone; glycol montanate; calcium carbonate; sucrose; magnesium stearate - microgynon 20 ed is indicated for the prevention of pregnancy.

MICROGYNON  30 Israel - engelsk - Ministry of Health

microgynon 30

bayer israel ltd - ethinylestradiol; levonorgestrel - coated tablets - levonorgestrel 150 mcg; ethinylestradiol 30 mcg - progestogens and estrogens, fixed combinations - oral contraceptive.

Microgynon 30 ED tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

microgynon 30 ed tablet blister pack

bayer australia ltd - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, sugar coated - excipient ingredients: purified talc; lactose monohydrate; macrogol 6000; sucrose; povidone; magnesium stearate; calcium carbonate; maize starch; glycol montanate - oral contraception

Microgynon 20 ED New Zealand - engelsk - Medsafe (Medicines Safety Authority)

microgynon 20 ed

bayer new zealand limited - ethinylestradiol 20ug; levonorgestrel 100ug - coated tablet - 20µg/100µg - active: ethinylestradiol 20ug levonorgestrel 100ug excipient: calcium carbonate glycerol glycol montanate iron oxide red iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone   purified talc purified water starch sucrose titanium dioxide calcium carbonate glycol montanate lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone   purified talc   sucrose - oral contraception

Dasatinib Teva 100 mg Film-coated Tablets Irland - engelsk - HPRA (Health Products Regulatory Authority)

dasatinib teva 100 mg film-coated tablets

teva b.v. - dasatinib - film-coated tablet - 100 milligram(s) - dasatinib

Dasatinib Teva 20 mg Film-coated Tablets Irland - engelsk - HPRA (Health Products Regulatory Authority)

dasatinib teva 20 mg film-coated tablets

teva b.v. - dasatinib - film-coated tablet - 20 milligram(s) - dasatinib

Dasatinib Teva 50 mg Film-coated Tablets Irland - engelsk - HPRA (Health Products Regulatory Authority)

dasatinib teva 50 mg film-coated tablets

teva b.v. - dasatinib - film-coated tablet - 50 milligram(s) - dasatinib

Dasatinib Teva 70 mg Film-coated Tablets Irland - engelsk - HPRA (Health Products Regulatory Authority)

dasatinib teva 70 mg film-coated tablets

teva b.v. - dasatinib - film-coated tablet - 70 milligram(s) - dasatinib

AZITHROMYCIN SANDOZ azithromycin (as dihydrate) 500mg tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

azithromycin sandoz azithromycin (as dihydrate) 500mg tablet blister pack

sandoz pty ltd - azithromycin dihydrate, quantity: 524.1 mg (equivalent: azithromycin, qty 500 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; maize starch; sodium lauryl sulfate; sodium starch glycollate type a; colloidal anhydrous silica; lactose monohydrate; hypromellose; titanium dioxide; macrogol 4000 - azithromycin is indicated for use in adults for the treatment of the following infections of mild to moderate severity: 1. lower respiratory tract infections: acute bacterial bronchitis due to streptococcus pneumoniae, haemophilus influenzae or moraxella catarrhalis.community acquired pneumonia due to streptococcus pneumoniae or haemophilus influenzae in patients suitable for outpatient oral treatment. community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. in clinical studies efficacy has been demonstrated against chlamydia pneumoniae, haemophilus influenzae, legionella pneumophilia, moraxella catarrhalis, mycoplasma pneumoniae, staphylococcus aureus and streptococcus pneumoniae. 2. upper respiratory tract infections: acute sinusitis due to streptococcus pneumoniae or haemophilus influenzae. acute streptococcal pharyngitis. note: penicillin is the usual drug of choice in the treatment of streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. azithromycin appears to be almost as effective in the treatment of streptococcal pharyngitis. however, substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present. 3. uncomplicated skin and skin structure infections: uncomplicated infections due to staphylococcus aureus, streptococcus pyogenes or streptococcus agalactiae. abscesses usually require surgical drainage. 4. sexually transmitted diseases: uncomplicated urethritis and cervicitis due to chlamydia trachomatis. . note: at the recommended dose azithromycin cannot be relied upon to treat gonorrhoea or syphilis. as with other medicines for the treatment of non-gonococcal infections, it may mask or delay the symptoms of incubating gonorrhoea or syphilis. appropriate tests should be performed for the detection of gonorrhoea or syphilis and treatment should be instituted as required. azithromycin is also indicated for the treatment of chlamydia trachomatis conjunctivitis and trachoma. azithromycin is also indicated for the prevention of infection due to mycobacterium avium-intracellular complex (mac) disease, when used as the sole agent or in combination with rifabutin at its approved dose, in adults and children aged more than 12 years with hiv infection and cd4 cell count less than or equal to 75 cells/microliter (see precautions). disseminated infection due to mycobacterium avium-intracellular complex should be excluded by a negative blood culture prior to commencement of therapy.